--- title: "Product Finished, Revenue Not Yet Started: The Mechanics of the Gap Between Two Capital Types" description: "The valley of death is the cash exhaustion that occurs in the interval between technical completion and revenue that covers operating expense. Its cause is not weak performance but the fact that capital types price different risks: early-stage capital buys optionality, growth capital buys repeatability, and lenders buy cash flow and collateral. The gap closes when the evidence calendar and the cash horizon are aligned on one page." url: https://www.beirek.com/en/blog/valley-of-death-cash-gap canonical: https://www.beirek.com/en/blog/valley-of-death-cash-gap published: 2025-12-14 modified: 2025-12-14 category: "Entrepreneurship" category_url: https://www.beirek.com/en/blog/category/entrepreneurship language: en-US reading_time_minutes: 8 publisher: BEIREK LLC publisher_url: https://www.beirek.com license: "© BEIREK LLC — citation with attribution and link permitted" keywords: ["valley of death","bridge financing","commercial repeatability","cash horizon","growth capital"] topics: ["Startup financing gap between product completion and sustainable revenue","Capital type segmentation by risk category in early-stage companies","Bridge round preference structures and their effect on subsequent pricing","Revenue quality diagnostics in commercial due diligence"] alternate_language_url: https://www.beirek.com/tr/blog/valley-of-death-cash-gap --- # Product Finished, Revenue Not Yet Started: The Mechanics of the Gap Between Two Capital Types > **In short:** The valley of death is the cash exhaustion that occurs in the interval between technical completion and revenue that covers operating expense. Its cause is not weak performance but the fact that capital types price different risks: early-stage capital buys optionality, growth capital buys repeatability, and lenders buy cash flow and collateral. The gap closes when the evidence calendar and the cash horizon are aligned on one page. *The moment technical risk closes is the moment financing risk opens, since completing the product exhausts the optionality that early-stage capital prices while failing to produce the repeatability that growth capital requires. This gap is not a market failure but the predictable consequence of capital segmenting by risk type, and it is managed on a calendar rather than by narrative.* --- In a board session, a file whose technical risk has largely closed arrives on the agenda in a structurally different form than the same file carried a year earlier. Where the debate once centered on whether the product would work at all, the first half of the presentation is now devoted to completed functionality, certifications obtained, and field test results, while the cash table settles at the end of the agenda, into a minute that rarely leaves room for discussion. Each technical milestone recounted by the team legitimizes deferring the financing question to the next meeting, and it does so honestly, because the progress being shown is real and optimism is its natural byproduct. Yet were the same session to ask how many months the balance in the account actually covers, the answer would prove to have no relationship whatsoever to the percentage of the product that has been completed. A second and more determinative observation concerns how the bridge financing conversation opens. That conversation almost never arrives as a planned movement of capital, structured twelve months in advance and sequenced against a set of milestones; it opens instead once the calendar has tightened, generally with three to four months of cash remaining, in the form of an interim request directed at existing shareholders. By that point the distribution of negotiating leverage around the table has shifted entirely from where it stood six months earlier, the company having delivered the product while the capital has not yet seen its return, with the consequence that the party setting the price is no longer the party generating the progress. Terms discussed under a shortening runway are terms discussed by one side only, whatever the formal symmetry of the conversation may suggest. The interval in question is the valley of death, that financing void in which the product exists technically, first customers have been signed, and revenue nonetheless fails to carry operating expense, leaving the company owned naturally by neither early-stage nor growth capital. The origin of the void lies not in company performance but in the fact that capital types price fundamentally different risks. Early-stage capital purchases optionality, meaning the magnitude of the market that opens if the technology functions as intended. Growth capital purchases repeatability, meaning demonstrated evidence that the same sale can be executed at the same cost, by someone other than the founder, more than once. A lender purchases neither, underwriting instead predictable cash flow and enforceable collateral, and none of these three mandates substitutes for another regardless of how the round is labeled in the deck. Completion of the product is precisely what renders the first of these three pricing logics inapplicable. Optionality is consumed at the moment the prototype runs, because the outstanding question ceases to be a technical one; commercial repeatability, meanwhile, has not yet been produced, since what exists in hand amounts to a handful of reference installations and contracts that are frequently pilot in character, carrying no committed obligation to repeat. The company thereby settles into a position between two pricing regimes, evaluable by the criteria of neither, and in that position the cost of capital does not rise so much as access to capital simply closes. The distinction matters more than it first appears: an elevated cost of capital remains a subject of negotiation, whereas the absence of access does not. This gap is not a market failure, and under specific conditions it performs a disciplinary function, since the segmentation of capital by risk type imposes a distinct standard at each stage and thereby limits the waste of resources. A company that cannot reach growth capital before producing commercial evidence is a company prevented from replicating an unproven model at scaled cost, which is the outcome the segmentation is designed to produce. The difficulty resides not in the mechanism but in the fact that the company binds its spending rhythm and its evidence-production rhythm to two different calendars: the engineering organization generates fixed monthly cost from the first day, while commercial evidence production is typically not initiated until the product is deemed finished. The condition has changed; the behavior has remained constant. The first layer of institutional cost registers on the calendar. On the side of an institutional or public buyer, the chain running from vendor registration through security review, technical approval, and budget allocation consumes, in most cases, the full length of a budget cycle, with the order landing not in the quarter when the technical decision was made but when the appropriation of the following fiscal year is released. Adding the lead time required for manufacturing or installation and the collection terms that follow, it is unremarkable for the first meaningful cash receipt to arrive one to two budget periods after technical approval. The cash horizon of the company, however, is seldom constructed to that length, financing need having been assumed to decline once the product was complete, when in fact a lengthening sales chain increases the working capital requirement rather than reducing it. The second layer sits in the capital structure. The genuine cost of a bridge round opened after the calendar has tightened lies not in its nominal interest or discount rate but in the preference architecture the documents carry: a liquidation preference greater than one times, participating preferred, a conversion discount constructed without a valuation cap, and adjustment provisions tied to the price of the subsequent round. Such terms deliver cash in the short term while distorting the pricing anchor of the round that follows, because an incoming investor, inheriting the existing structure, protects its own return either by pulling the aggregate valuation downward or by making a restructuring of the stack a condition precedent to closing. Dilution of founder and employee holdings, in the ordinary case, originates not in the size of the round but in that restructuring demand. The third layer becomes visible at the diligence table. Findings that surface in the diligence of a company at this stage relate characteristically not to the magnitude of revenue but to its quality: whether the top line is composed of pilot and non-recurring items, what share the first three customers represent of total revenue, whether sales close in the absence of the founder's personal network, and whether the contracts carry renewal and price escalation provisions at all. Where one of these headings proves weak, the transaction price does not fall; the price holds while the structure of payment changes, with a portion of consideration attached to an earn-out, the escrow percentage rising, and the scope of representations and warranties broadening. What determines valuation is not performance itself but the demonstrability of that performance as repeatable independently of the founder. Governing this interval is a matter of institutional architecture rather than individual foresight, and the architecture separates into four components. The first is defining the cash horizon by calendar rather than by stage label, so that the number of months the balance covers is reported identically every month, independently of the percentage of the product completed. The second is planning the commercial evidence chain ahead of the product roadmap, with the question of which evidence is produced for which customer type on which date constructed backward from the buyer's approval chain rather than forward from product features. The third is matching capital type to risk category rather than to a stage name, equipment finance corresponding to assets, prepaid customer contracts to delivery risk, and grants or incentives to technical maturity, none of them substitutable by an equity round. The fourth is maintaining the decision record at the moment of proposal rather than at the moment of approval, since an assumption whose test date and threshold were never written down is, over time, treated as an established fact. BEIREK constructs the intervention at this stage within a single table, holding the cash horizon and the commercial evidence calendar on the same time axis, on the same page, with the distance between them measured monthly rather than narrated quarterly. Work on the contractual line focuses not on shortening the buyer's approval chain, which is rarely within the company's control, but on generating cash while that chain runs its course, through prepaid pilot structures, stage-based milestone billing, and partial collection arrangements tied to performance rather than to a bank guarantee. On the financing line, the capital requirement is disaggregated not into a single round but into layers, each answering a specific risk, with the trigger for each layer defined in advance so that it opens at the point when the evidence that layer requires has actually been produced. What proves critical in operating this rhythm is where decisions sit on the agenda. The cash horizon is reviewed before the technical progress presentation rather than after it; bridge financing is placed on the table when twelve months of runway remain rather than three; and the precondition of each round is recorded together with an explicit list of the evidence the next capital type will demand. A record constructed in that manner does not leave the institutional memory of the board to the recollection of individuals, so that when the following investor sits down, which assumption the company tested, on what date, and with what result becomes visible in documentary form, a visibility that in most negotiations carries more weight than the evidence itself, since it demonstrates that the company knew what it did not yet know. Most companies lost in this interval are lost not because the product failed to work but because the distance between the date the product began working and the date the money ran out was never measured; and that distance, once measured, becomes a variable capable of being managed, while unmeasured it remains nothing more than a surprise arriving on someone else's calendar. ## Key Points - Completing the product exhausts the optionality that an early-stage investor priced, yet it does not by itself generate the commercial repeatability that a growth investor requires before underwriting. - The vendor approval and budget allocation cycle of an institutional buyer typically runs longer than the company's remaining cash horizon, and this mismatch is the structural origin of the gap rather than any deficiency in the product. - A bridge round opened after the calendar has already tightened is expensive not through its headline price but through its preference architecture, which permanently distorts the pricing anchor of the following round. - At the diligence table, the diagnostic signal at this stage is not the size of revenue but its quality: pilot composition, customer concentration, and dependence on the founder's personal relationships. - The interval is governed by planning the commercial evidence chain before the product roadmap and by matching capital type to risk category rather than to a stage label. ## Questions ### At what precise point does the valley of death begin? It begins when technical risk has largely closed, meaning the product can be shown to work, and it continues until revenue reliably carries operating expense. The opening signal is not the absence of revenue but a change in the applicable capital type: for the investor pricing optionality the story has concluded, while for the investor pricing repeatability it has not yet started, leaving the company between two underwriting mandates. ### The product is ready but sales are not closing — is the problem the product or the financing? In most cases it is neither, but a calendar mismatch. The chain of vendor registration, technical approval, and budget allocation on the institutional buyer's side can consume a full budget period, with the technical decision and the release of the appropriation falling into different fiscal years. Further product development does not change that outcome; reconstructing the cash horizon against the buyer's approval chain does. ### What warrants attention if a bridge round becomes unavoidable? The genuine cost sits in the preference architecture rather than in the discount rate. A liquidation preference above one times, participating preferred, an uncapped conversion discount, and price adjustment provisions all deliver near-term cash while distorting the pricing anchor of the following round. When the incoming investor makes restructuring the stack a condition precedent to closing, dilution originates in that restructuring rather than in the size of the bridge itself. ### What does an investor actually examine at this stage? Revenue quality rather than revenue size: whether the top line consists of pilot and non-recurring items, what proportion the first few customers represent of total revenue, whether sales close without the founder's personal network, and whether contracts carry renewal and escalation provisions. Where these headings are weak the headline price generally holds while the payment structure shifts, with a larger earn-out portion and a higher escrow percentage. --- Source: https://www.beirek.com/en/blog/valley-of-death-cash-gap Publisher: BEIREK LLC — https://www.beirek.com